On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning ...

Eliquis (apixaban) is an oral tablet used to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.

For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban ...

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to ...

One group from each was given apixaban, dubbed TAH3311, with the other two given an Eliquis tablet. Results found the maximum plasma concentration in patients dosed with TAH3311 was equivalent to ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed ... the need for anticoagulation monitoring or dosage adjustment. Apixaban has multiple elimination ...